- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01002495
Gene Therapy for the Treatment of Chronic Stable Angina
A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia
Study Overview
Detailed Description
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States
- Northwestern Memorial Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 21 years, but less than or equal to 75 years.
- Stable chronic refractory angina classified as Canadian Cardiovascular Society (CCS) functional class II - IV
- Left ventricular ejection fraction (LVEF) of ≥30% and ≤ 50%;
- Clinical signs and symptoms of significant ischemia by treadmill test or Stress imaging (SPECT, Echo or CARDIAC MRI acceptable)
- Subjects must be able to complete a minimum of 3 minutes, but no more than 10 minutes on a Modified Bruce treadmill protocol.
- Patients on maximal medical therapy including at least 2 of the following (unless hemodynamic parameters or intolerance contraindicate their use):(a) Long acting nitrate, (b) Beta Blocker or (c) Calcium Channel Blocker (d) Ranolazine. Optimal medical regimen for each subject will be decided by the referring cardiologist or principal investigator. Patients must be on stable medical regimen for 30 days prior to enrollment.
- Coronary angiogram within 1 year to confirm the presence of coronary disease which is not amenable to standard revascularization procedures.
Candidates must not be eligible for any other revascularization procedures. The participant and his/her coronary film must have been discussed with an independent cardiac surgeon and must have been denied for CABG or PTCA. Participants who are marginal or poor candidates for conventional revascularization will be considered eligible if the risks of performing a CABG or PTCA procedure outweigh the potential benefit and/or such a procedure is unlikely to offer a worthwhile clinical benefit. The criteria defining such cases may include, but may not be limited to, the following examples:
- Diffuse or distal vessel disease
- Chronic occlusions
- Unprotected left main stenosis
- Tortuous or severely angulated vessels
- Severely calcified vessels
- Small vessels (< 2.5mm)
- Subjects with childbearing potential must take acceptable measure to prevent pregnancy during the course of the study.
- Subject capable of understanding with the protocol and signing the informed consent document prior to any study related procedure.
Exclusion Criteria:
- Subjects who have undergone a successful revascularization procedure within 6 months of enrollment;
- MI, unstable angina requiring > 24 hour hospitalization, or percutaneous coronary intervention, within last 90 days;
- Stroke or TIA within last 180 days;
- Predominant CHF symptoms;
- Hemodynamically significant severe primary valvular heart disease, unless corrected by a properly functional prosthetic valve;
- Uncontrolled hypertension as defined as systolic BP 170 mmHg or diastolic > 90 mmHg at baseline/ screening evaluation;
- Sustained ventricular tachycardia or automatic implantable cardiodefibrillator (AICD) firing within last 180 days;
- History of ventricular fibrillation;
- Use of the MyoStar catheter may not be appropriate for patients with prosthetic valves. Patients with a mechanical valve at risk for injury due to the interventional approach should be excluded;
- Subjects with any comorbidity that may interfere with the ability to perform a maximal treadmill test (e.g. severe arthritis, musculoskeletal disorders, COPD);
- Subjects with a history of malignancy, a known active malignancy, or a new screening finding of malignant neoplasm;
- Patients with family history of colon cancer in any first degree relative unless they have undergone a colonoscopy in the last 12 months with negative findings;
- Elevated PSA unless prostate cancer has been excluded;
Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination.
- Cataract surgery within 6 months of trial;
- Vascular lesions of the anterior segment of the eye (infection or ulceration of the cornea, rubeotic glaucoma, etc);
- Vascular lesions of the posterior segment of the eye or proliferative retinopathy in diabetics, macular edema, s/p photocoagulation for macular edema or proliferative retinopathy; nondiabetics with central or branch retinal vascular occlusions, sickle cell retinopathy, ischemic retinopathy due to retinal venous stasis or carotid artery disease);
- Choroidal new vessels associated with age-related macular degeneration, myopic degeneration, presumed ocular histoplasmosis syndrome, angioid streaks, pseudoxanthoma elasticum, or without ocular disease; and
- Large elevated choroidal nevi, choroidal vascular tumors (choroidal hemangioma), or melanomas.
- Chronic inflammatory disease (e.g. Crohn, Rheumatoid Arthritis);
- Active infectious disease and/or known to have tested positive for human immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- Specific laboratory values at Screening including: Hemoglobin < 9.0, g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, Creatinine > 2.0 mg/dL, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary;
- Patients have undergone enhanced external pulsation (EECP) treatment within the last 6 months;
- Pregnancy or lactation;
- Severe comorbidity associated with a reduction of life expectancy of less than 1 year;
- Exposure to any previous experimental angiogenic therapy and/or myocardial laser therapy; or therapy with another investigational drug within 180 days of enrollment or participation in any concurrent study that may confound the results of this study;
- Major psychiatric disorder in past 6 months;
- History of recent tobacco abuse (within past < 5 years);
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Eight endocardial injection for a total dose of 1mg VM202
|
Endocardial injections on Day 0.
|
Experimental: Cohort 2
Eight endocardial injections for a total dose of 2mg VM202
|
Endocardial injections on Day 0.
|
Experimental: Cohort 3
Twelve endocardial injections for a total dose of 3mg VM202
|
Endocardial injections on Day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary study objective is to evaluate safety and tolerability of a catheter-based, endocardial injection of different doses of VM202.
Time Frame: Days 1, 7, 14, 21, 30, 60, and 90, 6 and 12 months
|
Days 1, 7, 14, 21, 30, 60, and 90, 6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary objectives include the assessment of the angiogenic potential of VM202
Time Frame: one month, three months, six months and twelve months
|
one month, three months, six months and twelve months
|
Efficacy measures include exercise treadmill test, SPECT, cardiac MRI and change in use of anti-anginal medications.
Time Frame: Days 1, 7, 14, 21, 30, 60, and 90. 6 and 12 months
|
Days 1, 7, 14, 21, 30, 60, and 90. 6 and 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VMCAD-001/B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Gennaro SardellaCompletedAssess the Periprocedural Myocardial NecrosisItaly
-
Tehran University of Medical SciencesRecruitingMyocardial Infarction | Myocardial Ischemia | Myocardial StunningIran, Islamic Republic of
-
University of TurkuTurku University HospitalEnrolling by invitationMyocardial Infarction | Myocardial InjuryFinland
-
EZUS-LYON 1Active, not recruiting
-
Samsung Medical CenterCompletedMyocardial Infarction | Myocardial ReperfusionKorea, Republic of
Clinical Trials on VM202
-
Helixmith Co., Ltd.Completed
-
Helixmith Co., Ltd.TerminatedFoot Ulcer, DiabeticUnited States
-
Helixmith Co., Ltd.CompletedAmyotrophic Lateral SclerosisUnited States
-
Helixmith Co., Ltd.Completed
-
Helixmith Co., Ltd.Completed
-
Helixmith Co., Ltd.CompletedCritical Limb IschemiaUnited States, Korea, Republic of
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Northwestern UniversityNational Institute on Aging (NIA); Helixmith Co., Ltd.CompletedPeripheral Artery DiseaseUnited States
-
Helixmith Co., Ltd.CompletedPainful Diabetic NeuropathiesUnited States, Korea, Republic of
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States